Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$191.17 USD

191.17
9,472,615

+0.32 (0.17%)

Updated Oct 15, 2025 04:00 PM ET

After-Market: $190.75 -0.42 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 243)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

Large Cap Pharma Stocks Staging a Comeback in Second Half

by Indrajit Bandyopadhyay

Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.

    Zacks Equity Research

    J&J Submits NDA to the FDA for Depression Drug in Adults

    by Zacks Equity Research

    Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.

      Zacks Equity Research

      Geron Stock Up More Than 200% in 2018 So Far: Here's Why

      by Zacks Equity Research

      Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.

        Zacks Equity Research

        Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

        by Zacks Equity Research

        Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

          Zacks Equity Research

          AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

          by Zacks Equity Research

          AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

            Zacks Equity Research

            Bayer's Blood Thinner Xarelto Fails in Line Extension Studies

            by Zacks Equity Research

            Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.

              Zacks Equity Research

              AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma

              by Zacks Equity Research

              AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, BP, eBay and BCE

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, BP, eBay and BCE

                  Mark Vickery headshot

                  Top Research Reports for Johnson & Johnson, NIKE & BP

                  by Mark Vickery

                  Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NIKE (NKE) and BP (BP).

                    Zacks Equity Research

                    J&J to Appeal as Judge Confirms Jury Order in Talc Case

                    by Zacks Equity Research

                    Johnson & Johnson's (JNJ) suffers setback as Missouri judge confirms talc lawsuit jury verdict. The company intends to appeal against the decision.

                      Kinjel Shah headshot

                      Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio

                      by Kinjel Shah

                      The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.

                        Zacks Equity Research

                        Pacira (PCRX) Rides High on Robust Exparel Performance

                        by Zacks Equity Research

                        Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

                          Zacks Equity Research

                          VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market

                          by Zacks Equity Research

                          VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.

                            Sweta Killa headshot

                            4 Sector ETFs to Tap at New Highs

                            by Sweta Killa

                            While there are winners in many corners of the stock market, investors should tap the sectors that are expected to continue moving higher in the weeks ahead.

                              Zacks Equity Research

                              Glaxo Stock Up This Year So Far: Will the Rally Continue?

                              by Zacks Equity Research

                              After a relatively strong performance so far this year, let's see how things are shaping up for Glaxo (GSK) for the rest of the year.

                                Sweta Killa headshot

                                5 Hot Stocks in the Dow ETF Last Week

                                by Sweta Killa

                                Dow Jones closed at its highest level since February, We have highlighted the five best performing stocks of last week in its ETF.

                                  Zacks Equity Research

                                  Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

                                  by Zacks Equity Research

                                  Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

                                    Zacks Equity Research

                                    Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

                                    by Zacks Equity Research

                                    Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

                                      Zacks Equity Research

                                      Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?

                                      by Zacks Equity Research

                                      Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Zacks Equity Research

                                        Geron's Growth Depends on Continuation of Imetelstat Studies

                                        by Zacks Equity Research

                                        Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.

                                          Zacks Equity Research

                                          Shire, Shionogi File NDA for Intuniv for Adults in Japan

                                          by Zacks Equity Research

                                          Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

                                            Zacks Equity Research

                                            Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                                            by Zacks Equity Research

                                            Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

                                              Zacks Equity Research

                                              VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

                                              by Zacks Equity Research

                                              VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

                                                Sweta Killa headshot

                                                Q2 Earnings Drive Pharma ETFs Higher

                                                by Sweta Killa

                                                The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.

                                                  Zacks Equity Research

                                                  Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

                                                  by Zacks Equity Research

                                                  Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.